{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:44:34Z","timestamp":1790405074069,"version":"4.1.0"},"reference-count":54,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2023,1,2]]},"DOI":"10.1080\/17512433.2023.2138343","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T01:35:18Z","timestamp":1666316118000},"page":"61-71","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Clinical efficacy and safety of dasiglucagon in severe hypoglycemia associated with patients of type 1 diabetes mellitus: a systematic review and meta-analysis"],"prefix":"10.1080","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0654-5998","authenticated-orcid":false,"given":"Sagar","family":"Dholariya","sequence":"first","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Rajkot, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5024-970X","authenticated-orcid":false,"given":"Deepak","family":"Parchwani","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Rajkot, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-5950","authenticated-orcid":false,"given":"Siddhartha","family":"Dutta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Rajkot, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2397-9023","authenticated-orcid":false,"given":"Ragini","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Rajkot, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1391079"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-1062"},{"key":"#cr-split#-cit0003.1","unstructured":"Mathew TK, Tadi P. Blood glucose monitoring. [Updated 2021 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing"},{"key":"#cr-split#-cit0003.2","unstructured":"2022 Jan. Updated 2021 Aug 11]: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK555976\/"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050080"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2215"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.endinu.2020.01.002"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31320-5"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2480"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.2337\/cd20-as01"},{"key":"cit0010","unstructured":"Xeris Pharmaceuticals. Gvoke (glucagon) injection, for subcutaneous use: US prescribing information. 2021. Available from: https:\/\/www.gvokeglucagon.com\/. [Cited 2022 Aug 7]."},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S20633"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1002\/pdi.1960140204"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.4158\/EP15831.OR"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2021.107882"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2012.0290"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01531-z"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-021-03183-0"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2014.01.006"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1007\/s40267-022-00894-x"},{"key":"cit0020","volume-title":"European Association for the Study of Diabetes","author":"Macchi F","year":"2020"},{"key":"cit0021","unstructured":"National center for biotechnology information. PubChem compound summary for CID 126961379, dasiglucagon. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Dasiglucagon. [cited 2022 May 28]."},{"key":"cit0022","unstructured":"Zegalogue (dasiglucagon); prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214231s000lbl.pdf. [cited 2022 Aug 10]."},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1747432"},{"key":"cit0024","unstructured":"NCT02660008. Single doses of ZP4207 adm. sc to hypoglycemic TD1 pt. to describe the PK and PD of ZP4207 as comp. to marketed glucagon. [cited 2022 June 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02660008"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1216-4"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.4097\/kjae.2018.71.2.103"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1547"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12494"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1266"},{"key":"cit0032","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.4.1, The cochrane collaboration, 2020. Available from: https:\/\/training.cochrane.org\/online-learning\/core-software-cochrane-reviews\/revman\/revman-5-download\/download-and-installation. [cited 2022 May 29]."},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1402"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13562"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2995"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13220"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14475"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v12.i12.2036"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd6726"},{"key":"cit0040","unstructured":"Zegalogue (dasiglucagon) injection, for subcutaneous use Initial U.S. Approval: 2021. Approval: 2021: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214231s000lbl.pdf. [Last accessed on 2022 Jun 7]."},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2304"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2252"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0367"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1177\/1932296818757795"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0363"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.4.461"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1177\/193229681000400607"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.12.9.604"},{"key":"cit0049","unstructured":"Eli Lilly and Company BAQSIMI (glucagon) nasal powder 3 mg, the first and only nasally administered glucagon to treat severe hypoglycemia in adults and children with diabetes ages four years and older, approved by FDA. Available from https:\/\/investor.lilly.com\/news-releases\/news-release-details\/baqsimitm-glucagon-nasal-powder-3-mg-first-and-only-nasally. [cited 2022 Aug 10]."},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.5114\/pedm.2020.94390"},{"key":"cit0051","unstructured":"Beyond type 1 editorial team FDA approves first ready-to-use liquid stable glucagon Gvoke. Available from https:\/\/beyondtype1.org\/gvoke-hypopen-fda-approval. [cited 2022 Aug 10]."},{"key":"cit0052","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022)","author":"Higgins JPT","year":"2022"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2023.2138343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T05:57:59Z","timestamp":1673935079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2023.2138343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,2]]}},"alternative-id":["10.1080\/17512433.2023.2138343"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2023.2138343","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}